Vorsetuzumab mafodotin


Vorsetuzumab mafodotin is an antibody-drug conjugate directed to the protein CD70 designed for the treatment of cancer. It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F, a cytotoxic agent.
This drug was developed by Seattle Genetics, Inc. The drug completed phase I clinical trials for renal cell carcinoma, but development was discontinued in 2013.
No reason was given but SG plan to start clinical trials of SGN-CD70A in 2014.